The potential for renoprotection with incretin-based drugs
نویسندگان
چکیده
منابع مشابه
Cardiovascular consequences of drugs used for the treatment of diabetes: potential promise of incretin-based therapies.
Cardiovascular disease is the predominant cause of death in diabetic patients, and yet the cardiovascular benefits of traditional drug treatments for hyperglycemia have been elusive. Two new classes of diabetic drugs targeting the glucagon-like peptide-1 (GLP-1) incretin pathway have emerged. The GLP-1 receptor agonists reduce blood glucose levels by stimulating insulin and inhibiting glucagon ...
متن کاملIncretin-based drugs and the risk of congestive heart failure.
OBJECTIVE To determine whether the use of incretin-based drugs, including GLP-1 analogs and dipeptidyl peptidase-4 inhibitors, is associated with an increased risk of congestive heart failure (CHF) among patients with type 2 diabetes. RESEARCH DESIGN AND METHODS The U.K. Clinical Practice Research Datalink, linked to the Hospital Episode Statistics database, was used to conduct a cohort study...
متن کاملThe potential of incretin-based therapies in type 1 diabetes.
Finding a cure for type 1 diabetes (T1D) has been elusive. Incretin-based therapies, since their approval, have demonstrated their clinical utilities in type 2 diabetes (T2D). Yet, their potential clinical benefits in T1D remain to be appraised. GLP-1, in addition to its insulinotropic action in alleviating hyperglycemia, possesses beneficial effects in protecting progressive impairment of panc...
متن کاملPancreatic safety of incretin-based drugs--FDA and EMA assessment.
n engl j med 370;9 nejm.org february 27, 2014 794 likely that such efficacy will be shown until the vaccines are licensed and postmarketing surveillance commences. Recent evidence suggests that EV71 vaccines do not provide cross-protection against all circulating genetic lineages of EV71 or against coxsackievirus A16.5 Thus, the Chinese C4A-based vaccines may not generate protective immunity ag...
متن کاملNew drugs for the treatment of diabetes: part II: Incretin-based therapy and beyond.
This is the second of a 2-part series focusing on newer therapies for type 2 diabetes and their cardiovascular implications. In the first segment, we reviewed the thiazolidinediones, highlighting emerging data concerning their cardiovascular effects, both positive and negative. Here, we present a corresponding discussion of the newest antihyperglycemic category, modulators of the incretin syste...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Kidney International
سال: 2014
ISSN: 0085-2538
DOI: 10.1038/ki.2014.236